Skip to main content
. 2023 Sep 28;11(19):e15829. doi: 10.14814/phy2.15829

FIGURE 2.

FIGURE 2

Baricitinib is associated with reduced in vitro migratory capacity of effector CD4+ T cells. (a) In vitro migration assay; schematic view of experimental setup. (b) In vitro migration of CD4+ T cells from RA patients (HC: w/o, n = 15; tofa [in vitro], n = 5; bari [in vitro], n = 5; RA: w/o, tofa [in vivo] and bari [in vivo], n = 10; RA: tofa [in vitro] and bari [in vitro], n = 5). Where indicated, CD4+ T cells from untreated RA patients or from healthy controls were incubated in vitro with tofacitinib or baricitinib for 24 h prior to the migration assay. (c) Gating strategy for the identification of FoxP3+CD127lowCD25high Treg cells. (d) In vitro Treg cell migration. HC, healthy controls; w/o, RA patients without current treatment; tofa, tofacitinib; bari, baricitinib. Data are presented as mean ± SD. Significance was calculated using one‐way ANOVA and Tukey's multiple comparison test.